Compare Marvell Technology Inc (MRVL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Zoetis Inc — how do they compare? Marvell Technology Inc trades at $220.65 (market cap $190.56B), while Zoetis Inc trades at $73.8 (market cap $31.14B). The key difference: Marvell Technology Inc is far larger — about 6.1× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| MRVL | ZTS | |
|---|---|---|
Market Cap | $190.56B | $31.14B |
Sector | Technology | Health |
52-Week High | $316.43 | $156.76 |
52-Week Low | $62.31 | $71.91 |
Enterprise Value | $191.99B | $38.70B |
Dividend Yield | 0.11% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $221.86, up 6.38% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and revenue growth to $5.77 billion in 2025. Analyst consensus remains strongly bullish with 82% buy ratings and a $275.68 price target, representing 24% upside potential. Recent news highlights Marvell's positioning in AI infrastructure and optical networking leadership.
Marvell presents significant growth potential driven by AI data center expansion and custom chip programs with Microsoft and NVIDIA. However, investors face risks from premium valuations (P/E 72.96), supply chain constraints, and competitive pressure from Broadcom and AMD. The stock's recent volatility and high beta characteristics require careful risk management despite strong institutional support.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
